Author Archive: Jeremy Parkinson

Morning Call For Thursday, May 3

Morning Call For Thursday, May 3

Overnight Markets and News Jun E-mini S&Ps (ESM18 +0.03%) this morning are up +0.21% on signs of strong corporate quarterly earnings results with Kraft Heinz and Tableau Software both up 5% in pre-market trading after they reported better-than-expected Q1 profits. European stocks are down -0.34% on deflation concerns after Eurozone Apr core CPI rose +0.7% […]
EURUSD: Time For An Upwards Correction

EURUSD: Time For An Upwards Correction

Previous: On Wednesday the 2nd of May, trading on the euro closed down. The single currency has shed 146 pips against the greenback over the May holidays to reach 1.1938. The pair went on a rollercoaster ride following the US Federal Reserve’s interest rate decision. The FOMC decided to maintain its key federal funds rate within […]
Indian Indices End Marginally Lower

Indian Indices End Marginally Lower

After witnessing volatile trades during the day, Indian share markets ended their session marginally lower. Losses were largely seen in the realty sector, capital goods sector and IT sector, while metal stocks ended the day higher. At the closing bell, the BSE Sensex stood lower by 73 points (down 0.2%) and the NSE Nifty closed lower by 38 points (down 0.4%). The BSE Mid Cap index ended the day […]
AUDUSD Daily Analysis – Thursday, May 3

AUDUSD Daily Analysis – Thursday, May 3

AUDUSD remains in the downtrend from 0.7813. As long as the price is below the falling trend line on the 4-hour chart, the bounce from 0.7472 could be treated as consolidation for the downtrend, and a breakdown below 0.7472 support could trigger another fall towards 0.7350. On the upside, a clear break above the trend […]
BTC/USD And BTC/JPY Forecast – Thursday, May 3

BTC/USD And BTC/JPY Forecast – Thursday, May 3

BTC/USD Bitcoin markets did very little during the day on Wednesday, hovering above the $9000 level, but that’s about it. The market seems to have a lot of noise between here and $10,000 above, so it’s not until we break above the $10,000 level that I think we can pick up any type of momentum. […]
All That Glitters

All That Glitters

There’s a lady who’s sure all that glitters is gold, so why doesn’t she have it in her portfolio? Yes, there are two paths you can go by… The world’s most precious metal is not only a safe haven when stocks are falling, it is also a classic hedge when inflation expectations are rising. Yesterday’s update from the Federal Reserve […]
Netflix, Expedia & Microsoft: 3 Trending Stocks Ready For Take-Off

Netflix, Expedia & Microsoft: 3 Trending Stocks Ready For Take-Off

While Amazon (Nasdaq:AMZN) and Apple Inc. (Nasdaq:AAPL) have undeniably eclipsed the headlines this week, I took to the Street to shine the spotlight on other large-cap stocks ready for take-off. Now let’s unravel what makes these 3 trending stocks so exciting right now: Netflix (Nasdaq:NFLX) Streaming giant Netflix is soaring right now. The company- which […]
What Tesla Can Teach Us About The High-Yield Bond Market

What Tesla Can Teach Us About The High-Yield Bond Market

Tesla may be a great company that builds exciting cars, but we wonder if investors are being compensated enough to lend Tesla money. Given its current state of production, Tesla burns mountains of cash and has routinely undershot guidance on delivering cars to eager customers. As a result, free cash flow has been negative since the inception […]
Respite To Dollar Short Squeeze

Respite To Dollar Short Squeeze

The euro bounced after being drilled to support in the $1.1930 area post-FOMC yesterday. The recovery has not been derailed by a shocking miss on the preliminary April CPI. Headline CPI slipped to 1.2% from 1.3%, but the more meaningful miss was the slump in the core rate to 0.7% from 1.0%. Recall that the […]
Regeneron Pharmaceuticals: Sequencing Its Way To +30% Upside

Regeneron Pharmaceuticals: Sequencing Its Way To +30% Upside

In the quest for a GARP stock with room to run, low short interest, positive free cash flow, a surprising find dropped out of the screener. Regeneron meets all of these prerequisites, plus delivers on high margins, steady top- and bottom-line growth, great management ratios, and an expanding drug portfolio. The C-suite continues to invest […]